Cargando…
Mitochondrial dysfunction is a key pathological driver of early stage Parkinson’s
BACKGROUND: The molecular drivers of early sporadic Parkinson’s disease (PD) remain unclear, and the presence of widespread end stage pathology in late disease masks the distinction between primary or causal disease-specific events and late secondary consequences in stressed or dying cells. However,...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9461181/ https://www.ncbi.nlm.nih.gov/pubmed/36076304 http://dx.doi.org/10.1186/s40478-022-01424-6 |
_version_ | 1784786921283649536 |
---|---|
author | Toomey, Christina E. Heywood, Wendy E. Evans, James R. Lachica, Joanne Pressey, Sarah N. Foti, Sandrine C. Al Shahrani, Mesfer D’Sa, Karishma Hargreaves, Iain P. Heales, Simon Orford, Michael Troakes, Claire Attems, Johannes Gelpi, Ellen Palkovits, Miklos Lashley, Tammaryn Gentleman, Steve M. Revesz, Tamas Mills, Kevin Gandhi, Sonia |
author_facet | Toomey, Christina E. Heywood, Wendy E. Evans, James R. Lachica, Joanne Pressey, Sarah N. Foti, Sandrine C. Al Shahrani, Mesfer D’Sa, Karishma Hargreaves, Iain P. Heales, Simon Orford, Michael Troakes, Claire Attems, Johannes Gelpi, Ellen Palkovits, Miklos Lashley, Tammaryn Gentleman, Steve M. Revesz, Tamas Mills, Kevin Gandhi, Sonia |
author_sort | Toomey, Christina E. |
collection | PubMed |
description | BACKGROUND: The molecular drivers of early sporadic Parkinson’s disease (PD) remain unclear, and the presence of widespread end stage pathology in late disease masks the distinction between primary or causal disease-specific events and late secondary consequences in stressed or dying cells. However, early and mid-stage Parkinson’s brains (Braak stages 3 and 4) exhibit alpha-synuclein inclusions and neuronal loss along a regional gradient of severity, from unaffected-mild-moderate-severe. Here, we exploited this spatial pathological gradient to investigate the molecular drivers of sporadic PD. METHODS: We combined high precision tissue sampling with unbiased large-scale profiling of protein expression across 9 brain regions in Braak stage 3 and 4 PD brains, and controls, and verified these results using targeted proteomic and functional analyses. RESULTS: We demonstrate that the spatio-temporal pathology gradient in early-mid PD brains is mirrored by a biochemical gradient of a changing proteome. Importantly, we identify two key events that occur early in the disease, prior to the occurrence of alpha-synuclein inclusions and neuronal loss: (i) a metabolic switch in the utilisation of energy substrates and energy production in the brain, and (ii) perturbation of the mitochondrial redox state. These changes may contribute to the regional vulnerability of developing alpha-synuclein pathology. Later in the disease, mitochondrial function is affected more severely, whilst mitochondrial metabolism, fatty acid oxidation, and mitochondrial respiration are affected across all brain regions. CONCLUSIONS: Our study provides an in-depth regional profile of the proteome at different stages of PD, and highlights that mitochondrial dysfunction is detectable prior to neuronal loss, and alpha-synuclein fibril deposition, suggesting that mitochondrial dysfunction is one of the key drivers of early disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-022-01424-6. |
format | Online Article Text |
id | pubmed-9461181 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-94611812022-09-10 Mitochondrial dysfunction is a key pathological driver of early stage Parkinson’s Toomey, Christina E. Heywood, Wendy E. Evans, James R. Lachica, Joanne Pressey, Sarah N. Foti, Sandrine C. Al Shahrani, Mesfer D’Sa, Karishma Hargreaves, Iain P. Heales, Simon Orford, Michael Troakes, Claire Attems, Johannes Gelpi, Ellen Palkovits, Miklos Lashley, Tammaryn Gentleman, Steve M. Revesz, Tamas Mills, Kevin Gandhi, Sonia Acta Neuropathol Commun Research BACKGROUND: The molecular drivers of early sporadic Parkinson’s disease (PD) remain unclear, and the presence of widespread end stage pathology in late disease masks the distinction between primary or causal disease-specific events and late secondary consequences in stressed or dying cells. However, early and mid-stage Parkinson’s brains (Braak stages 3 and 4) exhibit alpha-synuclein inclusions and neuronal loss along a regional gradient of severity, from unaffected-mild-moderate-severe. Here, we exploited this spatial pathological gradient to investigate the molecular drivers of sporadic PD. METHODS: We combined high precision tissue sampling with unbiased large-scale profiling of protein expression across 9 brain regions in Braak stage 3 and 4 PD brains, and controls, and verified these results using targeted proteomic and functional analyses. RESULTS: We demonstrate that the spatio-temporal pathology gradient in early-mid PD brains is mirrored by a biochemical gradient of a changing proteome. Importantly, we identify two key events that occur early in the disease, prior to the occurrence of alpha-synuclein inclusions and neuronal loss: (i) a metabolic switch in the utilisation of energy substrates and energy production in the brain, and (ii) perturbation of the mitochondrial redox state. These changes may contribute to the regional vulnerability of developing alpha-synuclein pathology. Later in the disease, mitochondrial function is affected more severely, whilst mitochondrial metabolism, fatty acid oxidation, and mitochondrial respiration are affected across all brain regions. CONCLUSIONS: Our study provides an in-depth regional profile of the proteome at different stages of PD, and highlights that mitochondrial dysfunction is detectable prior to neuronal loss, and alpha-synuclein fibril deposition, suggesting that mitochondrial dysfunction is one of the key drivers of early disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-022-01424-6. BioMed Central 2022-09-08 /pmc/articles/PMC9461181/ /pubmed/36076304 http://dx.doi.org/10.1186/s40478-022-01424-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Toomey, Christina E. Heywood, Wendy E. Evans, James R. Lachica, Joanne Pressey, Sarah N. Foti, Sandrine C. Al Shahrani, Mesfer D’Sa, Karishma Hargreaves, Iain P. Heales, Simon Orford, Michael Troakes, Claire Attems, Johannes Gelpi, Ellen Palkovits, Miklos Lashley, Tammaryn Gentleman, Steve M. Revesz, Tamas Mills, Kevin Gandhi, Sonia Mitochondrial dysfunction is a key pathological driver of early stage Parkinson’s |
title | Mitochondrial dysfunction is a key pathological driver of early stage Parkinson’s |
title_full | Mitochondrial dysfunction is a key pathological driver of early stage Parkinson’s |
title_fullStr | Mitochondrial dysfunction is a key pathological driver of early stage Parkinson’s |
title_full_unstemmed | Mitochondrial dysfunction is a key pathological driver of early stage Parkinson’s |
title_short | Mitochondrial dysfunction is a key pathological driver of early stage Parkinson’s |
title_sort | mitochondrial dysfunction is a key pathological driver of early stage parkinson’s |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9461181/ https://www.ncbi.nlm.nih.gov/pubmed/36076304 http://dx.doi.org/10.1186/s40478-022-01424-6 |
work_keys_str_mv | AT toomeychristinae mitochondrialdysfunctionisakeypathologicaldriverofearlystageparkinsons AT heywoodwendye mitochondrialdysfunctionisakeypathologicaldriverofearlystageparkinsons AT evansjamesr mitochondrialdysfunctionisakeypathologicaldriverofearlystageparkinsons AT lachicajoanne mitochondrialdysfunctionisakeypathologicaldriverofearlystageparkinsons AT presseysarahn mitochondrialdysfunctionisakeypathologicaldriverofearlystageparkinsons AT fotisandrinec mitochondrialdysfunctionisakeypathologicaldriverofearlystageparkinsons AT alshahranimesfer mitochondrialdysfunctionisakeypathologicaldriverofearlystageparkinsons AT dsakarishma mitochondrialdysfunctionisakeypathologicaldriverofearlystageparkinsons AT hargreavesiainp mitochondrialdysfunctionisakeypathologicaldriverofearlystageparkinsons AT healessimon mitochondrialdysfunctionisakeypathologicaldriverofearlystageparkinsons AT orfordmichael mitochondrialdysfunctionisakeypathologicaldriverofearlystageparkinsons AT troakesclaire mitochondrialdysfunctionisakeypathologicaldriverofearlystageparkinsons AT attemsjohannes mitochondrialdysfunctionisakeypathologicaldriverofearlystageparkinsons AT gelpiellen mitochondrialdysfunctionisakeypathologicaldriverofearlystageparkinsons AT palkovitsmiklos mitochondrialdysfunctionisakeypathologicaldriverofearlystageparkinsons AT lashleytammaryn mitochondrialdysfunctionisakeypathologicaldriverofearlystageparkinsons AT gentlemanstevem mitochondrialdysfunctionisakeypathologicaldriverofearlystageparkinsons AT revesztamas mitochondrialdysfunctionisakeypathologicaldriverofearlystageparkinsons AT millskevin mitochondrialdysfunctionisakeypathologicaldriverofearlystageparkinsons AT gandhisonia mitochondrialdysfunctionisakeypathologicaldriverofearlystageparkinsons |